|  | CSP | SSP2 | LSA1 | LSA3 | EXP1 |
---|
Site | Vol. | D44,D49 | D46,D47 | D51-D59 | D64-D68 | D70,D72 | D60,D61 |
---|
Urban
| 113 | 295 | 145 | 283 | 233 | 208 | Â |
 | 614 |  |  |  | 103 |  |  |
 | 815 |  |  |  | 110 |  |  |
 | 816 |  |  |  | 83 |  |  |
 | 917 |  |  |  | 250 |  | 70 |
 | 1123+ |  |  |  | 365 |  |  |
Rural
| 1324 | Â | Â | 90 | 88 | Â | 245 |
 | 1326 | 85 |  | 140 | 100 | 98 | 113 |
 | 1330+ |  |  |  | 200 |  | 103 |
 | 1331 |  |  | 150 | 193 |  | 318 |
 | 1332 |  |  | 243 |  | 343 |  |
 | 1341 | 83 |  | 100 |  | 210 | 168 |
 | 1342 |  |  | 430 |  |  |  |
 | 1345 |  |  | 95 |  |  |  |
 | 1351+ |  |  |  | 70 |  |  |
- All 30 volunteers were tested with DR peptides from CSP (four), SSP2/TRAP (nine), EXP1 (two), LSA1 (five) and LSA3 (two), except for volunteer 1340, who was not tested against LSA3. Six of 13 urban and nine of 17 rural volunteers had ELISpot activities that were identified as positive and are listed in this table. Each number represents the mean of quadruplicate wells in a single assay expressed as sfc/m, with medium controls subtracted. A "+" next to the volunteer identification number in the second column indicates patent parasitemia at the time the sample was taken [see Methods]. The peptides that were not recognized by any of the volunteers as well as the volunteers not having any positive responses are shown in Additional File 5.